<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822793</url>
  </required_header>
  <id_info>
    <org_study_id>18CH052</org_study_id>
    <secondary_id>2018-004552-37</secondary_id>
    <nct_id>NCT03822793</nct_id>
  </id_info>
  <brief_title>A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty</brief_title>
  <acronym>PRADO</acronym>
  <official_title>Dose Study of Tranexamic Acid in Total Hip Replacement to Reduce Post-operative Hemoglobin Loss: A Phase 2 Randomized Double-blind Monocentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single preoperative dose of tranexamic acid (TXA) reduces blood loss and red blood cell
      transfusion in primary hip arthroplasty. Numerous regimens have been tested, ranging from
      10mg/kg up to 3g. However the optimal dose to administer is unknown.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This dose-response study is a randomized double blind study with five groups of 50 patients
      each. Patients will be randomized to placebo, tranexamic acid (TXA) 500 mg, tranexamic acid
      (TXA) 1000 mg, tranexamic acid (TXA) 1500 mg or tranexamic acid (TXA) 3000mg. In addition a
      pharmacokinetic/pharmacodynamic study will be performed to identify the contribution of
      tranexamic acid (TXA) plasma concentration as a predictor of intra and postoperative D-Dimer
      values.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">June 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>randomized double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>haemoglobin decrease in the perioperative period</measure>
    <time_frame>Day 8</time_frame>
    <description>Percentage of haemoglobin change in the perioperative period. It requires the sampling of haemoglobin before surgery and on the eighth postoperative day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of the concentration of tranexamic acid</measure>
    <time_frame>Day 8</time_frame>
    <description>For tranexamic acid pharmacokinetics, the outcome measure is the sampling of tranexamic blood concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the concentration of D-Dimer</measure>
    <time_frame>Day 8</time_frame>
    <description>For tranexamic acid pharmacodynamics, the outcome is the sampling of D-Dimer levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>allogenic red blood cell transfusion</measure>
    <time_frame>Day 8</time_frame>
    <description>For allogenic red blood cell transfusion, the outcome measure will be the percentage of patients that will receive the transfusion of at least one allogenic red blood cell unit in the perioperative period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe anaemia</measure>
    <time_frame>Day 8</time_frame>
    <description>For severe anaemia (defined as a level of haemoglobin &lt;10 gram by deciliter), the outcome measure will be the percentage of patients that will have at least one value of haemoglobin &lt;10 gram by deciliter in the perioperative period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of symptomatic thrombotic events and death</measure>
    <time_frame>Day 8</time_frame>
    <description>For the incidence of symptomatic thrombotic events and death, the outcome measure is a combined criteria of venous events (deep venous thrombosis or pulmonary embolism), arterial events (acute coronary syndrome, stroke or peripheral arterial thrombosis) and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of a seizure</measure>
    <time_frame>Day 8</time_frame>
    <description>Upon the occurrence of a seizure, the endpoint is a clinical endpoint involving either the observation of a generalized tonic-clonic seizure or a partial seizure or absence with epilepsy confirmed by an electroencephalogram interpreted by a blind neurologist in the patient's inclusion group.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Arthropathy of Hip</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will be included in this group by randomization and they will receive a perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 10 minutes just before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: perfusion of 500 mg Exacyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be included in the group 2 by randomization and they will receive a perfusion of 500mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: perfusion of 1000 mg Exacyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be included in the group 2 by randomization and they will receive a perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: perfusion of 1500 mg Exacyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be included in the group 3 by randomization and they will receive a perfusion of 1500 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: perfusion of 3000 mg Exacyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be included in the group 4 by randomization and they will receive a perfusion of 3000mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patient will receive a perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 10 minutes just before surgery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1: perfusion of 500 mg Exacyl</intervention_name>
    <description>Patient will receive a perfusion of 500mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.</description>
    <arm_group_label>Group 1: perfusion of 500 mg Exacyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2: perfusion of 1000 mg Exacyl</intervention_name>
    <description>Patient will receive a perfusion of 1000mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.</description>
    <arm_group_label>Group 2: perfusion of 1000 mg Exacyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 3: perfusion of 1500 mg Exacyl</intervention_name>
    <description>Patient will receive a perfusion of 1500mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.</description>
    <arm_group_label>Group 3: perfusion of 1500 mg Exacyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 4: perfusion of 3000 mg Exacyl</intervention_name>
    <description>Patient will receive a perfusion of 3000mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.</description>
    <arm_group_label>Group 4: perfusion of 3000 mg Exacyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient requiring primary hip arthroplasty (less than 3 months)

          -  Consent of the patient or a family member or the support person

        Exclusion Criteria:

          -  Contraindication to tranexamic acid

          -  Contraindication to apixaban

          -  Pregnancy

          -  Patient receiving a curative anticoagulating treatment in the preoperative period

          -  Bilateral or previous hip arthroplasty

          -  Hemorrhagic surgery less than 2 weeks old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien LANOISELEE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien LANOISELEE, MD</last_name>
    <phone>(0)477828554</phone>
    <phone_ext>+33</phone_ext>
    <email>julien.lanoiselee@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Béatrice DEYGAS, CRA</last_name>
    <phone>(0)477127655</phone>
    <phone_ext>+33</phone_ext>
    <email>beatrice.deygas@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Julien LANOISELEE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul ZUFFEREY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie GALLAND-CARNESECCHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Yves BIEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cédric DELZANNO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre LAMBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Malik BAROUDI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zeina PRADES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 31, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tranexamic acid (TXA)</keyword>
  <keyword>arthroplasty</keyword>
  <keyword>hip</keyword>
  <keyword>Exacyl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

